$VOR

Vor Biopharma Inc. (VOR): Submission of Matters to a Vote of Security Holders

Vor Biopharma Inc. (VOR) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. EX-10.1 2 vor-ex10_1.htm EX-10.1 EX-10.1 321452236 v8 Vor Biopharma Inc. Amended and Restated 2021 Equity Incentive Plan Adopted by the Board of Directors: April 16, 2026 Approved by the Stockholders: June 11, 2026 321452236 v8 Table of Contents Page 1. General. 1 2. Shares Subje

Original reporting
Published Jun 12, 2026, 8:11 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 12, 2026, 8:17 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefCorporate actions
Primary signal
$VOR
Neutral
medium confidence
Mentioned
$VOR
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$VORNeutralLow
01

Why it matters

The key new information is stockholder approval of the amended plan, which governs future equity awards and share reserve capacity; the provided excerpt does not include any new clinical or financial guidance.

02

Market read

Primarily affects equity-compensation/dilution expectations rather than near-term business performance.

03

What to watch

Traders may focus on the plan’s share reserve mechanics (initial cap plus recurring increases) when assessing longer-term dilution, even if near-term fundamentals are unchanged.

Relevance 6/10Novelty 4/10Timing: Filed June 12, 2026 (8-K) after stockholder approval on June 11, 2026

Background

The 8-K Item 5.07 reports matters submitted to a vote of security holders, including approval of an amended and restated equity incentive plan.

Company-level read

Ticker impact

$VORNeutralMedium confidence
Context

Vor Biopharma filed an 8-K disclosing stockholder approval of an amended and restated 2021 Equity Incentive Plan (approved June 11, 2026).

Expected impact

Likely limited/short-lived impact; any reaction would be more about dilution optics than new business fundamentals.

Evidence & confidence

The filing is a corporate governance/compensation plan update with no new clinical, financial, or deal terms disclosed in the provided text.

Market effects

Routine equity incentive plan updates are common in biotech; no sector-wide signal is provided here.

None indicated.

None indicated.

Counterpoint

If the plan includes an automatic annual share reserve increase (4% for 10 years), the market could re-rate dilution risk more than expected even without operating news.

Key entities

  • Vor Biopharma Inc.

    Company filing the 8-K and whose stockholders approved the amended and restated equity incentive plan.

  • Amended and Restated 2021 Equity Incentive Plan

    Equity compensation plan approved by stockholders on June 11, 2026; includes a share reserve and annual increase mechanics described in the exhibit.

Related articles

$VORMedAI 8/10

Vor Completes Enrollment of Global Phase 3 Upstream Mg Trial and Expands Telitacicept Global Franchise into Ocular Myasthenia Gravis

Vor Bio completed enrollment in its Phase 3 UPSTREAM MG trial for telitacicept, a treatment for generalized myasthenia gravis, with results expected in early 2027. The company plans to start a Phase 3 trial for ocular myasthenia gravis in the same timeframe, expanding its telitacicept franchise. The trials follow positive results from RemeGen's Phase 3 trial in China.

$DAICMed

CID HoldCo Received Notice of Delisting

Nasdaq plans to delist CID HoldCo (DAIC) for failing to meet listing requirements, including market value and late filings. The company has requested a hearing and seeks to transfer to Nasdaq Capital Market, claiming it meets the $2.5M stockholders' equity requirement after a recent transaction.